Bevicizumab and Thrombosis: Some Answers But Questions Remain

The study by Patel and colleagues reported in this issue verifies the increased risk of arterial thrombosis, but not venous thrombosis, with the receipt of bevacizumab. The focus of future research now needs to be on ameliorating this increased risk and identifying the mechanism for prothrombotic effects of targeted antineoplastic therapy.